• 1
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561566.
  • 2
    Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998; 4: 16611672.
  • 3
    Kantarjian H, Sawyers C, Hochhaus A, et al. International STI571 CML Study Group. Hematological and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 4
    Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103: 28732878.
  • 5
    Hoelzer D, Gokbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol. 2002; 39: 3237.
  • 6
    Ottman OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 19651971.
  • 7
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876880.
  • 8
    Corbin AS, La Rosee P, Stoffregen EP, Drucker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003; 101: 46114614.
  • 9
    Cowan-Jacob SW, Guez V, Griffin JD, et al. Bcr-Abl kinase mutations and drug resistance to imatinib (STI571) in chronic myelogenous leukemia. Mini Rev Med Chem. 2004; 4: 285299.
  • 10
    Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001; 293: 2163.
  • 11
    Ricci C, Scappini B, Divoky V, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 2002; 62: 59955998.
  • 12
    Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000; 95: 17581766.
  • 13
    Mahon FX, Deininger MB, Schultheis B, Chabrol Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96: 10701079.
  • 14
    Scappini B, Gatto S, Onida F, et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer. 2004; 100: 14591471.
  • 15
    Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003; 6: 231238.
  • 16
    Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004; 11: 3543.
  • 17
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers DL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399401.
  • 18
    Weisberg E, Manley P, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7: 129141.
  • 19
    Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005; 11: 49414947.
  • 20
    Estrov Z, Talpaz M, Zipf TF, et al. Role of GM-CSF in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL): studies on two newly established Ph1-positive cell lines (Z-119 and Z-181). J Cell Physiol. 1996; 166: 618630.
  • 21
    Beran M, Pisa P, O'Brien S, et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993; 53: 36033610.
  • 22
    Giles F, Kantarjian H, Wassmann B, et al. A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr/Abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL) [abstract]. Blood. 2004; 104: 10a11a.